Veligrotug is an intravenously administered anti-insulin-like growth factor-1 receptor antibody developed for the treatment of thyroid eye disease (TED). Veligrotug has demonstrated rapid reductions in diplopia as well as improvements in orbital inflammation, thereby highlighting its potential as a targeted biologic research tool in autoimmune ophthalmopathy.
Reinheit:
99.80%
CAS Nummer:
[2728655-31-8]
Target-Kategorie:
IGF-1R
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten